Placebo Response in Clinical Trials: Approaches to Mitigation

Industry trends show that a major contributor to trial failure is the increased rate of placebo response, while at the same time, placebo response across multiple therapeutic areas is now historically high and progressively increasing. Multiple reviews in different therapeutic areas including pain, neurology, psychiatry, dermatology, pediatric studies, etc. suggest a very distressing trend in that, year-over-year, the rates of placebo response are increasing dramatically.

The question we must ask ourselves: How can these trends be reversed?

Access this webinar to learn how to increase the chances of trial success in an uncertain world.

About the Author

Dr. Mark Opler, PhD, MPH | Chief Research Officer

Dr. Mark Opler serves as Chief Research Officer, directing scientific research and development at MedAvante-ProPhase. Dr. Opler was the founder of ProPhase and served as its CEO and Chief Scientific Officer among other positions. He holds the titles of Adjunct Assistant Professor of Psychiatry at New York University and Assistant Professor of Clinical Neuroscience at Columbia University’s College of Physicians and Surgeons. His academic research focuses on the etiology, phenomenology, and treatment of serious and persistent mental disorders. He is also leading the development of the new upcoming edition of the PANSS Manual©.

Follow on Linkedin More Content by Dr. Mark Opler, PhD, MPH | Chief Research Officer
Previous Post
Mind Map: Building a Framework for Measurement Reliability
Mind Map: Building a Framework for Measurement Reliability

Next Flipbook
Addressing Suggestibility as a Psychological Phenomenon in Clinical Trials
Addressing Suggestibility as a Psychological Phenomenon in Clinical Trials

It is important to understand patient perspectives and to anticipate how subjects in research studies may b...